Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of venetoclax and azacitidine in treating patients
with therapy related or secondary myelodysplastic syndrome. Venetoclax may stop the growth of
cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Chemotherapy
drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Giving venetoclax in combination with azacitidine may work better in treating patients with
therapy related or secondary myelodysplastic syndrome.